# Pirfenidone in Adult Hospitalized Patients With COVID-19

> **NCT05713292** · PHASE3 · COMPLETED · sponsor: **Capital Medical University** · enrollment: 168 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Pirfenidone Oral Product
- **DRUG:** Pirfenidone placebo

## Key facts

- **NCT ID:** NCT05713292
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2023-03-04
- **Final completion:** 2023-03-30
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05713292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05713292, "Pirfenidone in Adult Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05713292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*